Observational studyJournal of the American Heart Association2026
Contemporary Guideline-Directed Medical Therapy for Heart Failure in the United States: The EMPACE Study.
Observational study in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRandomized trials and clinical guidelines support early initiation of guideline-directed medical therapy (GDMT) for heart failure (HF). The EMPACE (Treatment Patterns of Guideline-Directed Medical Therapies in Heart Failure Patients in the Real-World) study examined GDMT use in US clinical practice among patients hospitalized with heart failure (HHF).
methodsThis observational cohort study examined US patient data from Optum's deidentified Market Clarity database (June 2020-September 2023). GDMT use was assessed in the 12 months before and after HHF. Discontinuation was assessed over 12 months after initiation.
resultsAmong 17 210 patients (73% HF with reduced ejection fraction [EF], 4%, HF with mildly reduced EF, 23% HF with preserved EF), mean age was 69.2 years, and 60% were male. Before HHF, among patients with HF with reduced EF (HFrEF), only 1% received quadruple therapy; use of individual therapies was beta blockers 68%, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers 64%, mineralocorticoid receptor antagonists 23%, angiotensin receptor-neprilysin inhibitors (ARNI) 14%, and sodium-glucose cotransporter-2 inhibitor (SGLT2i) 5%. After HHF, GDMT use improved modestly: quadruple therapy 2%, beta blockers 84%, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers 72%, mineralocorticoid receptor antagonists 38%, ARNI 26%, and SGLT2i 13%. Among patients receiving therapy post discharge, mean time-to-initiation was longest for SGLT2i (88 days) and shortest for beta blockers (15 days). Mean time-to-quadruple therapy was 109 days. ARNI had the highest 12-month discontinuation rate (62%), followed by mineralocorticoid receptor antagonists (57%), SGLT2i (55%), and beta blockers (51%). Among patients with HF with mildly reduced EF (HFmrEF) and HF with preserved EF (HFpEF), only 7% each received SGLT2i before HHF compared with 12% and 9% post-HHF (each with mean time-to-initiation 28 days), respectively.
conclusionsAmong patients hospitalized for HFrEF in contemporary US clinical practice, there were significant gaps in prehospitalization quadruple therapy and only modest GDMT improvement post-discharge, with delayed initiation and high discontinuation rates. Similar patterns were observed with SGLT2i among patients with HFmrEF and HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.